Nutriband Inc NTRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
Trading Information
- Previous Close Price
- $5.58
- Day Range
- $5.54–5.66
- 52-Week Range
- $2.83–9.10
- Bid/Ask
- $5.35 / $5.78
- Shares Outstanding
- 12.16M
- Market Cap
- $69.96M
- Volume/Avg
- 1,748 / 68,939
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 41.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- < 0.01%
Company Profile
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.nutriband.com
Valuation
Metric | NTRB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.72 |
Price/Sales | 41.81 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NTRB |
|---|---|
Quick Ratio | 3.80 |
Current Ratio | 4.21 |
Interest Coverage | −334.01 |
Quick Ratio
NTRB
Profitability
Metric | NTRB |
|---|---|
Return on Assets (Normalized) | −45.21% |
Return on Equity (Normalized) | −52.26% |
Return on Invested Capital (Normalized) | −50.03% |
Return on Assets
NTRB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|H!QXN@ | LOCK|tlk@T | $138B | |||
| Moderna Inc MRNA | LOCK|S^lXJKn | LOCK|vyv | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%n?^!$@ | LOCK|^d>CP | $93B | |||
| argenx SE ADR ARGX | LOCK|xsm%T#Z | LOCK|Dv | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?xx@MD | LOCK|dk | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!m@l!Q@! | LOCK|jlC&% | $30B | |||
| Incyte Corp INCY | LOCK|R@M&<d^ | LOCK|v% | $24B | |||
| BioNTech SE ADR BNTX | LOCK|%&X%C^G | LOCK|$$x | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|?gDYW@t | LOCK|dXsn@ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Rh&#$>< | LOCK|<$ | $15B |
United States